Literature DB >> 12559127

Behavioral sensitization to quinpirole is not associated with increased nucleus accumbens dopamine overflow.

Timothy E Koeltzow1, Jennifer D Austin, Paul Vezina.   

Abstract

This study assessed the relationship between extracellular nucleus accumbens (NAc) dopamine (DA) concentrations and sensitized locomotor activation following repeated administration of the DA D2-like receptor agonist quinpirole. Locomotor activity measures and nucleus accumbens microdialysis samples were collected concurrently in response to the first (acute) and tenth (repeated) quinpirole injection (0.5 mg/kg s.c., every other day). Results indicate that acute quinpirole produced locomotor activation and that repeated quinpirole resulted in locomotor sensitization. Acute quinpirole significantly decreased the detection of extracellular concentrations of DA and the DA metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the NAc. Following repeated quinpirole, basal NAc DA levels were decreased, whereas basal DOPAC levels were increased. Nevertheless, quinpirole challenge elicited a significant decrease in DA, DOPAC and HVA following repeated treatment. In addition, although acute quinpirole did not affect NAc levels of the serotonin metabolite 5-hydroxyindolacetic acid (5-HIAA), quinpirole challenge produced a significant increase in 5-HIAA levels following repeated treatment. Taken together, these data indicate that functional DA autoreceptor subsensitivity is not a necessary condition for the expression of behavioral sensitization to quinpirole. Instead, it appears that behavioral sensitization to quinpirole occurs predominantly as a consequence of neuroadaptations that are post-synaptic to DA release.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559127     DOI: 10.1016/s0028-3908(02)00328-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Dopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse.

Authors:  Derek B Oien; Andrea N Ortiz; Alexander G Rittel; Rick T Dobrowsky; Michael A Johnson; Beth Levant; Stephen C Fowler; Jackob Moskovitz
Journal:  J Neurochem       Date:  2010-03-31       Impact factor: 5.372

2.  Differential effects of clorgyline on sensitization to quinpirole in rats tested in small and large environments.

Authors:  Anna Dvorkin; Kirsten E Culver; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2006-05-11       Impact factor: 4.530

3.  Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.

Authors:  Shuichi Chiba; Tadahiro Numakawa; Midori Ninomiya; Hyung Shin Yoon; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

4.  Multigenerational effects of adolescent morphine exposure on dopamine D2 receptor function.

Authors:  John J Byrnes; Nicole L Johnson; Lindsay M Carini; Elizabeth M Byrnes
Journal:  Psychopharmacology (Berl)       Date:  2013-01-13       Impact factor: 4.530

5.  Effects of dorsal striatal infusions of R(-)-propylnorapomorphine on kappa-opioid-mediated locomotor activity in the young rat: possible role of the indirect pathway.

Authors:  S Charntikov; L R Halladay; M S Herbert; E M Marquez; S A McDougall
Journal:  Neuroscience       Date:  2008-06-14       Impact factor: 3.590

6.  Mechanisms of Kappa Opioid Receptor Potentiation of Dopamine D2 Receptor Function in Quinpirole-Induced Locomotor Sensitization in Rats.

Authors:  Angélica P Escobar; Marcela P González; Rodrigo C Meza; Verónica Noches; Pablo Henny; Katia Gysling; Rodrigo A España; José A Fuentealba; María E Andrés
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

7.  Nucleus accumbens core and pathogenesis of compulsive checking.

Authors:  Javier Ballester González; Anna Dvorkin-Gheva; Charmaine Silva; Jane A Foster; Henry Szechtman
Journal:  Behav Pharmacol       Date:  2015-02       Impact factor: 2.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.